Clinical trial · Interventional
Prediction of Delayed Toxic Cardiomyopathy in Children
Longitudinal Analysis of Myocardial Function by Speckle Tracking Echocardiography and Prediction of Delayed Toxic Cardiomyopathy Associated With Anthracycline Therapy in Children
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Analyses will be performed with data from included patients until the end of the inclusion period. The clinical team did not wish to extend the inclusion period in order not to delay the analyses.
Summary
Brief summary (as posted)
Longitudinal analysis of myocardial function using "Speckle Tracking Echocardiography" STE analysis and prediction of delayed toxic induced cardiomyopathy in young patients who received anthracycline therapy in childhood.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiotoxicity | — | UNRESOLVED | — |
| Childhood Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cardiac ultrasound with speckle tracking analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Anthra2
- description
- Patient will have an echocardiography with speckle tracking analysis 5 years after the end of their participation to "SpeckleAnthra" study (NCT02893787)
- interventionNames
- Diagnostic Test: cardiac ultrasound with speckle tracking analysis
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Cardiac ultrasound analysis with speckle tracking of age- and sex-matched healthy patients in the Anthra2 group
- interventionNames
- Diagnostic Test: cardiac ultrasound with speckle tracking analysis
Primary outcomes (1)
- measure
- Left Ventricle Global Longitudinal 2D strain (LVGLS) expressed in percentage and obtained from cardiac ultrasound cineloop of 2D 4,3 and 2 apical views analyzed by the Tomtec STE Software.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 11 Years
- Maximum age
- 27 Years
Show eligibility criteria text
ANTHRA GROUP Inclusion Criteria: * Patients who were treated with anthracyclines for malignant disease between the ages of 0 and 18 * Patient aged 11 to 27 years * Included in the "SpeckleAnthra" Study (NCT02893787) * Discontinued chemotherapy for more than 6 years * Patient in remission of malignant disease * Enrolled in a social security plan * Written informed consent from at least one legal representative for the minor patient/ Written informed consent for patients of legal age Exclusion Criteria: * Onset of active malignancy or recurrence of malignancy after the "Speckle Anthra" study that required resumption of chemotherapy or mediastinal radiotherapy. * Chronic cardiac, pulmonary or muscular pathology of etiology other than secondary to anthracycline therapy * For adult patients: subject under guardianship or curators CONTROL GROUP Inclusion Criteria: * Control patient included in the "Speckle Control" study (NCT02056925) * Had a cardiological consultation with echocardiography performed for a banal reason (heart murmur test, cardiological symptoms) and whose result was normal * No chronic disease or long-term drug treatment Exclusion Criteria: * Refusal to participate in the study by the patient and/or parents or legal guardian after receipt of the study's information and non-objection note.
References
Publications (1)
- BACKGROUNDAmedro P, Vincenti M, Abassi H, Lanot N, De La Villeon G, Guillaumont S, Gamon L, Mura T, Lopez-Perrin K, Haouy S, Sirvent A, Cazorla O, Vergely L, Lacampagne A, Avesani M, Sirvent N, Saumet L. Use of speckle tracking echocardiography to detect late anthracycline-induced cardiotoxicity in childhood cancer: A prospective controlled cross-sectional study. Int J Cardiol. 2022 May 1;354:75-83. doi: 10.1016/j.ijcard.2022.02.012. Epub 2022 Feb 12. PMID 35167907